GB9920558D0 - Methods for particle formation and their products - Google Patents

Methods for particle formation and their products

Info

Publication number
GB9920558D0
GB9920558D0 GBGB9920558.5A GB9920558A GB9920558D0 GB 9920558 D0 GB9920558 D0 GB 9920558D0 GB 9920558 A GB9920558 A GB 9920558A GB 9920558 D0 GB9920558 D0 GB 9920558D0
Authority
GB
United Kingdom
Prior art keywords
products
methods
particle formation
particle
formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9920558.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics UK Ltd
Original Assignee
Bradford Particle Design Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bradford Particle Design Ltd filed Critical Bradford Particle Design Ltd
Priority to GBGB9920558.5A priority Critical patent/GB9920558D0/en
Publication of GB9920558D0 publication Critical patent/GB9920558D0/en
Priority to EP00956682A priority patent/EP1207856A2/en
Priority to MXPA02001803A priority patent/MXPA02001803A/en
Priority to KR1020027002715A priority patent/KR20020047137A/en
Priority to PCT/GB2000/003328 priority patent/WO2001015664A2/en
Priority to GB0021227A priority patent/GB2355194B/en
Priority to CA002382556A priority patent/CA2382556A1/en
Priority to GB0220996A priority patent/GB2381453A/en
Priority to AU68550/00A priority patent/AU783570B2/en
Priority to JP2001519878A priority patent/JP2003508419A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0407—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solute
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0488—Flow sheets
GBGB9920558.5A 1999-08-31 1999-08-31 Methods for particle formation and their products Ceased GB9920558D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB9920558.5A GB9920558D0 (en) 1999-08-31 1999-08-31 Methods for particle formation and their products
JP2001519878A JP2003508419A (en) 1999-08-31 2000-08-31 Co-compounding methods and their products
PCT/GB2000/003328 WO2001015664A2 (en) 1999-08-31 2000-08-31 Coformulation methods and their products
MXPA02001803A MXPA02001803A (en) 1999-08-31 2000-08-31 Coformulation methods and their products.
KR1020027002715A KR20020047137A (en) 1999-08-31 2000-08-31 Coformulation methods and their products
EP00956682A EP1207856A2 (en) 1999-08-31 2000-08-31 Coformulation methods and their products
GB0021227A GB2355194B (en) 1999-08-31 2000-08-31 Coformulation methods and their products
CA002382556A CA2382556A1 (en) 1999-08-31 2000-08-31 Coformulation methods and their products
GB0220996A GB2381453A (en) 1999-08-31 2000-08-31 Active/polymer coformulations
AU68550/00A AU783570B2 (en) 1999-08-31 2000-08-31 Coformulation methods and their products

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9920558.5A GB9920558D0 (en) 1999-08-31 1999-08-31 Methods for particle formation and their products

Publications (1)

Publication Number Publication Date
GB9920558D0 true GB9920558D0 (en) 1999-11-03

Family

ID=10860085

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9920558.5A Ceased GB9920558D0 (en) 1999-08-31 1999-08-31 Methods for particle formation and their products
GB0021227A Expired - Fee Related GB2355194B (en) 1999-08-31 2000-08-31 Coformulation methods and their products

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB0021227A Expired - Fee Related GB2355194B (en) 1999-08-31 2000-08-31 Coformulation methods and their products

Country Status (8)

Country Link
EP (1) EP1207856A2 (en)
JP (1) JP2003508419A (en)
KR (1) KR20020047137A (en)
AU (1) AU783570B2 (en)
CA (1) CA2382556A1 (en)
GB (2) GB9920558D0 (en)
MX (1) MXPA02001803A (en)
WO (1) WO2001015664A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1376146B (en) 1999-12-08 2011-04-06 法马西亚公司 Solid-state form of celecoxil having enhanced bioavailability
CH694686A5 (en) 2000-03-04 2005-06-15 Eco2 Sa Product micronization of pharmaceutical substances.
FR2815540B1 (en) † 2000-10-19 2005-06-10 Separex Sa PROCESS FOR MANUFACTURING VERY FINE PARTICLES COMPRISING A PRINCIPLE INSERTED IN A HOST MOLECULE
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0102075D0 (en) 2001-01-26 2001-03-14 Astrazeneca Ab Process
AU2002310567B2 (en) * 2001-05-30 2005-10-20 Csir Method of encapsulating an active substance
US20050260273A1 (en) * 2001-06-07 2005-11-24 Chinea Vanessa I Applicatin of a bioactive agent in a solvent composition to produce a target particle morphology
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
JP2004534812A (en) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク Pharmaceutical composition of dispersion of drug and neutral polymer
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
CA2464308A1 (en) 2001-10-22 2003-05-01 Dompe S.P.A. Supercritical fluids processing: preparation of protein microparticles and their stabilisation
EP1446104B2 (en) 2001-11-01 2011-08-03 Novartis AG Spray drying methods
CA2474838C (en) 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US7354601B2 (en) 2003-05-08 2008-04-08 Walker Stephen E Particulate materials
ATE540671T1 (en) 2003-08-04 2012-01-15 Bend Res Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DRUG ADSORBATES AND LIPOPHILIC MICROPHASE-FORMING MATERIALS
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
ES2390183T3 (en) 2006-10-11 2012-11-07 Crititech, Inc. Method of precipitation of small particles of medicine in use container
GB0702402D0 (en) 2007-02-08 2007-03-21 Thar Pharmaceuticals Inc Method of creating crystalline substances
KR20090129998A (en) 2007-02-11 2009-12-17 맵 파마슈티컬스, 인코포레이티드 Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
AU2008331967B2 (en) 2007-12-07 2012-10-25 Xspray Microparticles Ab Method and arrangement for the production of particles
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
MX350838B (en) 2011-02-11 2017-09-18 Grain Proc Corporation * Salt composition.
AU2013208323B2 (en) * 2012-01-13 2017-07-06 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
DK2802314T3 (en) * 2012-01-13 2021-01-25 Xspray Microparticles Ab METHOD OF MANUFACTURE OF STABLE, AMORPHEY HYBRID NANOPARTICLES WHICH INCLUDE AT LEAST ONE PROTEIN CHINESE INHIBITOR AND AT LEAST ONE POLYMER STABILIZING AND MATRIX-FORMING COMPONENT

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
EP0462066A1 (en) * 1990-06-15 1991-12-18 Warner-Lambert Company Amorphous gemfibrozil
DE4041563A1 (en) * 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh METHOD FOR PRODUCING ACTIVE MICROPARTICLES FROM HYDROLYTICALLY DEGRADABLE POLYMERS
IT1255792B (en) * 1992-08-05 1995-11-16 Bayer Italia Spa PHARMACEUTICAL COMPOSITIONS FOR THE ORAL ADMINISTRATION OF DIHYDROPYRIDINS IN THE FORM OF DRINK
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
SI9500173B (en) * 1995-05-19 2002-02-28 Lek, Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
AU709384B2 (en) * 1996-03-01 1999-08-26 University Of Kansas, The Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
WO1997044028A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
FR2753639B1 (en) * 1996-09-25 1998-12-11 PROCESS FOR THE PREPARATION OF MICROCAPSULES OF ACTIVE MATERIALS COATED WITH A POLYMER AND NOVEL MICROCAPSULES OBTAINED IN PARTICULAR BY THE PROCESS
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
IT1296464B1 (en) * 1997-11-19 1999-06-25 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF DRUG-LOADED CROSS-LINKED POLYMER POWDERS AND RELATED PREPARATION PROCESS BY MEANS
DE19821951A1 (en) * 1998-05-15 1999-11-18 Basf Ag Orally administered solid or liquid cyclosporin compositions
US6465011B2 (en) * 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
GB9915975D0 (en) * 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles

Also Published As

Publication number Publication date
AU6855000A (en) 2001-03-26
KR20020047137A (en) 2002-06-21
WO2001015664A2 (en) 2001-03-08
WO2001015664A3 (en) 2001-09-20
AU783570B2 (en) 2005-11-10
GB0021227D0 (en) 2000-10-18
JP2003508419A (en) 2003-03-04
MXPA02001803A (en) 2004-02-26
CA2382556A1 (en) 2001-03-08
EP1207856A2 (en) 2002-05-29
GB2355194A (en) 2001-04-18
GB2355194B (en) 2003-01-08

Similar Documents

Publication Publication Date Title
GB9920558D0 (en) Methods for particle formation and their products
GB2354765B (en) Dispersion composition and method for producing the same
AU2373200A (en) Apparatuses and methods for forming assemblies
EP1230016A4 (en) Particle production apparatus
IL148073A0 (en) Apparatus and methods for the production of powders
HUP0104914A3 (en) Galenicformulations fast disintegrating the mouth and method for preparing same
EP1198184A4 (en) Appliqu method and article
AU1957201A (en) Methods and systems for selecting travel products
HK1047125A1 (en) Systems and methods for producing and using fine particle materials
IL146808A0 (en) Methods for coating particles and particles produced thereby
AU6027300A (en) Methods and means for producing improved dairy products
GB9928490D0 (en) Products and processes therefor
AU2001274740A1 (en) High density products and method for the preparation thereof
AU1064800A (en) Products and methods
HK1048889A1 (en) Component and method for the production thereof
HUP0105166A3 (en) Substances wk-5344a and wk-5344b and process for producing the same
GB0017586D0 (en) Method and means for particle measurement
AU6449500A (en) Method for obtaining health-promoting products and resulting products
EP1172442A4 (en) Vitamin d derivatives and process for producing the same
AU7738600A (en) Reduced gravity transformation process and product
AU5751200A (en) Detergent particles and methods for making them
AU7023300A (en) Product and method
GB9912059D0 (en) Products and methods
GB9914202D0 (en) Products and methods
GB9917273D0 (en) Products and methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)